BNET Industries
Market Cap:$3.3M
Last Fiscal Year Sales:$2.7M
- Public
Dow Jones Description
Datastand is a technology company that developed Internet software and distributes financial data. Datastand's Financial Database contains fundamental corporate data on almost 3000 companies quoted on the OTC-BB and is provided in 28 fields of data. Datastand can license the database content to customers in a variety of formats. Key elements of our strategy include: o INCREASE CLIENT BASE. We intend to expand our sales force to target businesses in industries that require robust online market analysis tools and financial information on their web sites. o INCREASE NUMBER OF PRODUCTS AVAILABLE. We intend to expand our product offerings to include other equity markets in North America and Europe. This will allow us to better serve the online financial information needs of our clients and their users. o USING TECHNOLOGY TO LEVERAGE OUR GROWTH. We intend to develop and market innovative products and services to attract and retain clients. o PURSUE STRATEGIC ALLIANCES OR ACQUISITIONS. We intend to seek strategic alliances which would complement our products or services or to give us access to new markets.
Chief Executive Officer
Robert BakkerContact Information
8333 Weston Road
Suite 106
Woodbridge L4L 8E2
4166265346
Peer Companies
NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414
News & Analysis
Filter by
metabolic research inc. - All News and Analysis
Metabolic Research, Inc. Elects Bradford van Siclen to its Board
LAS VEGAS -- Metabolic Research, Inc. (OTCBB:MTBR) announced today the election of Bradford van Siclen to its Board of Directors. Brad van Siclen has a MBA from New York University's Stern School of Business with emphasis on Finance and Accounting. His career includes Vice President, Investment Banking with Commonwealth Associates,...
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Robert Bakker | Chief Executive Officer |
| David Brown | Chief Financial Officer (Principal Financial Officer) |
| Allison Carlo | Vice President |
| Emil Schandl | Vice President |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Jonathan Robert Sanders Arch | Board of Directors |
| Usha Sriram | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Metabolic Research, Inc. | Chief Executive Officer | Current |
| Mtbr | Vice President of National Sales | Current |
| Organization | Position | Status |
|---|---|---|
| Metabolic Research, Inc. | Chief Financial Officer (Principal Financial Officer) | Current |
| Organization | Position | Status |
|---|---|---|
| Metabolic Research, Inc. | Vice President | Current |
| Organization | Position | Status |
|---|---|---|
| Metabolic Research, Inc. | Vice President | Current |
| Organization | Position | Status |
|---|---|---|
| Metabolic Research, Inc. | Board of Directors | Current |
| Glenmark | Board of Directors | Current |
| Organization | Position | Status |
|---|---|---|
| Webhealthcentre.Com | Current | |
| The Endocrine Society | Board of Directors | Current |
| Metabolic Research, Inc. | Board of Directors | Current |
| American Association of Clinical Endocrinologists, Inc. | Board of Directors | Current |
Executive News
-
Metabolic Research, Inc. Reports 22% Sales Increase
-
Metabolic Research, Inc. Reports 22% Sales Increase
-
Metabolic Research Names New VP of Marketing
-
Metabolic Research, Inc. Appoints New VP of Marketing
| Volume | 23,200 |
| Shares Outstanding | 55.8M |
| Market Cap | 3.3M |
| Year High | 0.10 |
| Year Low | 0.022 |
| Earnings Per Share | -0.020 |
| P/E Ratio | N/A |
| Dividend | 0.00 |
| Yield | 0.00 |
Industry Transcripts by Seeking Alpha
-
Alexza Pharmaceuticals, Inc., Q3 2009 Earnings Call Transcript
on Nov 09, 2009about ALXA
-
Salix Pharmaceuticals Ltd Q3 2009 Earnings Call Transcript
on Nov 09, 2009about SLXP
-
ACADIA Pharmaceuticals, Inc. Q3 2009 Earnings Conference Call
on Nov 09, 2009about ACAD
-
XOMA Ltd. Q3 2009 Earnings Call Transcript
on Nov 09, 2009about XOMA
-
Halozyme Therapeutics, Inc. Q3 2009 Earnings Call Transcript
on Nov 06, 2009about HALO
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted 3 votes
- The 10 Weirdest Drug Stories of the Month 3 votes
- Fired Whistleblower Reps Make Similar Claim: Pfizer Said They Lacked "Integrity" 3 votes

